......LookN for Gold
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well timed news for GILD - chart appreciates it lol
FDA OKs Gilead's remdesivir
Oct. 22, 2020 4:01 PMGilead Sciences, Inc. (GILD)By: Douglas W. House, SA News Editor
The FDA's website indicates that it has fully approved Gilead Sciences' (GILD +0.8%) Veklury (remdesivir). It does not specify the specific indication, but the company completed its rolling application in early August for severely ill hospitalized COVID-19 patients.
The agency granted emergency use authorization (EUA) for these patients on May 1.
Update: The nod is for adults and pediatric patients at least 12 years old and weighing at least 40 kg with COVID-19 requiring hospitalization.
The FDA has also issued a new EUA for Veklury for hospitalized pediatric patients under 12 years of age and weighing at least 3.5 kg or hospitalized pediatric patients weighing 3.5 kg to less than 40 kg with suspected or laboratory confirmed COVID-19 for whom the use of an intravenous agent is clinically appropriate
$AEMD $1.74 added...20dma over 50dma(200ma at $1.79)
$XELB $1.10 added...20ma crossing 50ma- price above 200sma
$DGLY $2.10 - wow cheapies imo
$LMFA .67 - chart is set imo
$ADIL $2.14 News out ...chart is set
$TMBR shaping up...,
$TMBR 1.34 here we go
$TMBR 1.26 setting up nicely
$VOC added some
SPI $8.19 - on watch here,
$AMBD - .01 minimum buyout (from Twitter)~~>>>
American Moblie Dental going to be sold per all stock transaction of AMBD....
850m common o/s...
no preferred
no r/s
debt wiped from books
Cash value right around $8.5 million...
Gives a buyout value of .01...
$GOVX (small float) ~>>> JUST OUT: SCHEDULE 13G Cavalry Fund I Management LLC 6.8% stake !
https://www.sec.gov/Archives/edgar/data/832489/000155335020000947/cavalry_geovax13g.htm
$GOVX ~>>> JUST OUT: SCHEDULE 13G Cavalry Fund I Management LLC 6.8% stake !
https://www.sec.gov/Archives/edgar/data/832489/000155335020000947/cavalry_geovax13g.htm
$GOVX ~>>> JUST OUT: SCHEDULE 13G Cavalry Fund I Management LLC 6.8% stake !
https://www.sec.gov/Archives/edgar/data/832489/000155335020000947/cavalry_geovax13g.htm
Speaking of bounces ~~>>>> $ANCN $1.20 range....Relentless from $2.51 hod
JAKK News out....$4.6
Or buy low, sell high
***GOVX*** small float ~~>>> (Aug news) Company Demonstrated Progress on COVID-19 Vaccine Development;
Continued Progress in Other Infectious Disease and Immuno-Oncology Programs
https://www.globenewswire.com/news-release/2020/08/10/2075674/0/en/GeoVax-Reports-2020-Second-Quarter-Financial-Results-and-Provides-Corporate-Update.html
***GOVX*** small float ~~>>> (Aug news) Company Demonstrated Progress on COVID-19 Vaccine Development;
Continued Progress in Other Infectious Disease and Immuno-Oncology Programs
https://www.globenewswire.com/news-release/2020/08/10/2075674/0/en/GeoVax-Reports-2020-Second-Quarter-Financial-Results-and-Provides-Corporate-Update.html
***THMO News out >>> Facilitating the 'Vaccine Era' of COVID-19 Response: ThermoGenesis to Receive U.S. Patent for Breakthrough Serological Test Reader Technology
RANCHO CORDOVA, Calif., Oct. 20, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO) today announced that it has received notification from the United States Patent and Trademark Office (USPTO) of its intent to issue U.S. Patent No. 10,823,746 on November 3, for the Company's new breakthrough lateral flow immunoassay test reader technology, the ThermoGenesis Reader. The application leading to this patent, titled, "Lateral Flow Immunoassay Test Reader and Method of Use," was accepted by USPTO under its recently announced COVID-19 Prioritized Examination Program.
The ThermoGenesis Reader's technology is specifically designed to facilitate the efficient utilization of America's COVID-19 vaccine stocks as we enter 'The Vaccine Era' of COVID-19 response. For more information please visit https://thermogenesis.com/covid-19-test-kit/
As the United States Centers For Disease Control and Prevention (CDC) explains in its recent guidance to public health programs on how to plan and operationalize their vaccination responses:[1] "A key point to consider is that vaccine supply will be limited at the beginning of [America's national immunization] program." The CDC illustrated this with a hypothetical scenario in which only 15 million doses might be available three months after the first vaccine is approved.
Anticipating the potential need for a 'seronegatives first' triage strategy while vaccine supplies are limited, ThermoGenesis has designed its new reader technology to facilitate the widespread use of inexpensive, mass-produced, FDA-authorized SARS-CoV-2 lateral flow immunoassay (LFIA) tests to distinguish seropositive members of populations of concern (individuals who already have SARS-CoV-2 antibodies), who might therefore be a lower priority for the earliest immunization. Seronegative members of these populations of concern (individuals altogether lacking SARS-CoV-2 antibodies) could thereby be prioritized.
"We have consulted with leading public health experts from industry, government and academia who have advised us that U.S. Food and Drug Administration (FDA) authorization of the first COVID-19 vaccines won't be the beginning of the end of this pandemic, but rather the end of the beginning," said Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis. "The challenge we are addressing comes in anticipation of an initially limited vaccine supply that will be administered on a prioritized basis to only a small fraction of the population. Our innovative technology, the ThermoGenesis Reader, is a robust, inexpensive, widely deployable, easy-to-use solution that will enable the tracking of vaccine recipients' antibody response over time, both to presumptively confirm immune status and to determine when booster immunizations may be required by individuals whose initial vaccine responses are waning. Lateral flow immunoassays are the fastest, least expensive, and most readily mass-produced serological tests for the kind of high-volume testing this will require, and the portable precision of the ThermoGenesis Reader will unleash LFIA's power to help carry us through to the ultimate eradication of this virus through an optimally efficient immunization strategy."
ThermoGenesis plans to complete current beta testing of its new reader and enter into production in December, in time for the anticipated approval of one or more vaccines around the end of this year.
Key features of the ThermoGenesis reader's design include:
High precision and sensitivity of laser-scanning densitometry, for quantitative photometric detection and photometric quantification of positive test results.
Hand-held, and rechargeable battery-power, for use anywhere authorized LFIA tests are administered, indoors or out.
Unique and fully automated self-calibration, ensuring each Reader, in any operator's hands, will produce the same photometric results for a given test cartridge.
Novel technology that makes laser scanning without powered moving parts possible, reliable, and inexpensive.
Connected data technology for upload of test scan data to a cloud-connected database. Scan data is securely digitally signed on the reader to ensure the integrity of data both in motion and at rest.
Instant (less than 3 seconds) quantitative photometric readouts.
The industry's lowest-priced LFIA reader without sacrificing high performance, thanks to its uniquely efficient patent-protected technology.
The ThermoGenesis Reader will accept only LFIA cartridges that have been validated for use with the reader and certified by ThermoGenesis. The FDA-authorized COVID-19 LFIA cartridge manufactured by BioHit Healthcare (EUA200192/S002) is the first cartridge to receive this certification. Work is currently under way with additional manufacturers who are seeking ThermoGenesis certification for their own products.
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpressâ„¢ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.
Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
[1] COVID-19 Vaccination Program: Interim Playbook for Jurisdiction Operations (2020). Centers for Disease Control.
https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf
https://c212.net/c/img/favicon.png?sn=NY63424&sd=2020-10-20 View original content:http://www.prnewswire.com/news-releases/facilitating-the-vaccine-era-of-covid-19-response-thermogenesis-to-receive-us-patent-for-breakthrough-serological-test-reader-technology-301155423.html
SOURCE ThermoGenesis Holdings, Inc.
***$SPI moving here.....
***$SPI gearing up ....possible runner ahs
Switched over to $BABA $297.50 Puts...sold calls for loss
$RMSL in watch for 004 break
$MDJH added here for a swing....
$RYCEY 2.78 on watch
$ZCMD 2.04 nhod
$HUSN .70 nice pullback opportunity
$RCON - can be a good swing from here....1.26+ close bullish imo
$CHNR - 1.40 break could send it
$ADIL - 1.75~1.80 levels on watch
$HAPP - 1.85 worth a peek
$GOVX - lookN good here
$ITP $5 in sight?!! Wow
$ITP $1.10 hod....stock halted
In some $BABA $317.50 weekly calls
$GOVX $THMO $ITP shaping up nicely.....
$VCNX $CJJD $ITP $MDJH